Clinical Trials

Several clinical trials evaluate 6-Benzylaminopurine across diverse biological contexts, including healthy participants, frontal fibrosing alopecia, and hypertension, operating under Early Phase 1 or non-applicable phase designations. Sponsored by academic and medical entities—including Case Western Reserve University, The Cleveland Clinic, the University of Minnesota, the University of Arizona, and the American Heart Association—these protocols currently maintain a recruitment status of not yet recruiting.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04333290 Not yet recruiting
Healthy
Robert Fox|Case Western Reserve University|The Cleveland Clinic
 2025-03 Early Phase 1
NCT03335228 Not yet recruiting
Frontal Fibrosing Alopecia
University of Minnesota
 2025-03-01 Not Applicable
NCT05744817 Not yet recruiting
Hypertension
University of Arizona|American Heart Association
 2024-11-15 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 6-Benzylaminopurine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

6-Benzylaminopurine acts as a synthetic cytokinin that regulates the enzymatic activity of plant antioxidant defense systems to promote cell development and growth. This modulation of cellular stress responses and growth pathways provides a mechanistic rationale for exploring physiological outcomes in clinical trials addressing healthy cohorts, frontal fibrosing alopecia, and hypertension.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.